(Q35578893)

9 August 2017

1 reference

title

Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes (English)

1 reference

9 August 2017

Bridging the Treatment Gap: Improving Compliance With Lipid‐Modifying Agents and Therapeutic Lifestyle Changes (English)

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Cardiology and cardiovascular medicine

30 March 2024

main subject

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

30 March 2024

author name string

Thomas Pearson

1

1 reference

9 August 2017

Laurie Kopin

2

1 reference

9 August 2017

language of work or name

1 reference

1 January 2003

1 reference

full work available at URL

9 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1520-037X.2003.02633.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14605514

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1520-037X.2003.02633.x

30 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1520-037X.2003.02633.x

30 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

30 March 2024

published in

Preventive Cardiology

1 reference

9 August 2017

6

1 reference

9 August 2017

4

1 reference

9 August 2017

204-211

1 reference

Current perspectives on statins

9 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2003.02633.X

Understanding and Improving Patient Compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2003.02633.X

A case-management system for coronary risk factor modification after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2003.02633.X

The undertreatment of LDL-cholesterol: addressing the challenge

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

30 March 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

30 March 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

30 March 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

The therapeutic gap--compliance with medication and guidelines

30 March 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

From best evidence to best practice - what are the obstacles?

30 March 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

30 March 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

30 March 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

30 March 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

30 March 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

30 March 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

30 March 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

30 March 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

30 March 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

30 March 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance

30 March 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Intensive lifestyle changes for reversal of coronary heart disease

30 March 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

30 March 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

30 March 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Drug treatment of lipid disorders

30 March 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

30 March 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

30 March 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

30 March 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

30 March 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Clinical treatment of dyslipidemia: practice patterns and missed opportunities

30 March 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Apparent discontinuation rates in patients prescribed lipid-lowering drugs.

30 March 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

30 March 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Effect of a single high-fat meal on endothelial function in healthy subjects

30 March 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease

30 March 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study

30 March 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Poor adherence with hypolipidemic drugs: a lost opportunity

30 March 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Patients' beliefs about treatment: the hidden determinant of treatment outcome?

30 March 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness

30 March 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial.

30 March 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality

30 March 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Pharmaceutical care services and results in project ImPACT: hyperlipidemia.

30 March 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Persistence of use of lipid-lowering medications: a cross-national study

30 March 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial.

30 March 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world"--randomized controlled trial

30 March 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

30 March 2024

48

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

30 March 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

30 March 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1520-037X.2003.02633.X

30 March 2024

Identifiers

1 reference

9 August 2017

1 reference